ClinicalTrials.gg
RecruitingNCT07782944Updated Aug 24, 2026

CD38 Targeted -PET/ CT for Multiple Myeloma

An interventional study of standard-of-care imaging (FDG PET/CT), CD38 PET/CT in Multiple Myeloma (MM), Lymphoma, Large B-Cell, Diffuse (DLBCL), Lymphoma, sponsored by Guilin Medical University, China. Recruiting at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-08-24.

Sponsored by Guilin Medical University, China · Not applicable, Interventional, and Diagnostic

From the registry’s dates

  • Started Jul 2026; still recruiting 4 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
100
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 448 studies in Multiple Myeloma with a site in China — 238 open to participants now, 275 under way, 47 of them phase 3. Multiple Myeloma · China.

Planned enrollment
102nd of 406
100 · median 40
Started
2026
with 53 others
No phase
43 of 448
26 open now
Primary completion
2030-12
later than 262 of 274 live
Registered
439th of 448
by date

Among the 448 studies in Multiple Myeloma with a site in China, this one is the 102nd largest by planned enrollment of the 406 interventional ones that give a count, is one of 54 that started in 2026, is one of 43 with no phase, reaches primary completion later than 262 of the 274 other live ones, and was the 439th registered.

Multiple Myeloma

3,763 studies on the registry are indexed under Multiple Myeloma; 770 are open to participants now.

Browse Multiple Myeloma studies →

Open to participants now

238 of the 448 studies in Multiple Myeloma with a site in China are open now. Recruiting first, the newest first:

232 more — sign in →

All 238 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 585 Multiple Myeloma studies recruiting now, 430 (74%) set no upper age limit and 106 (18%) stop at 75 or younger; 36 take children under 18; 24 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 448 studies in Multiple Myeloma with a site in China, or all of them as a file.
02

Study summary

The objective of the study is to construct a noninvasive approach CD38 targeted PET/CT to detect tumor lesions in patients with Multiple Myeloma and to compare with FDG PET/CT.

Read the detailed description

CD38 targeting PET radiotracer is promising as an excellent imaging agent applicable to Multiple Myeloma. In this research, subjects with Multiple Myeloma or highly suspected recurrence detection underwent contemporaneous CD38 PET/CT and standard-of-care imaging (FDG PET/CT) either for an initial assessment or for metastases or highly suspected recurrence detection. Tumor uptake was quantified by the maximum standard uptake value (SUVmax). The numbers of positive tumor lesions of standard-of-care imaging and FDG PET/CT were recorded by visual interpretation. The diagnostic accuracy of CD38 PET/CT was calculated and compared to standard-of-care imaging.

03

Conditions studied

  • Multiple Myeloma (MM), Lymphoma, Large B-Cell, Diffuse (DLBCL), Lymphoma

Keywords

  • CD38
  • PET/CT
  • radiotracer
  • Multiple Myeloma
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adult patients (aged 18 years or older);
  • Patients with newly diagnosed, highly suspected recurrence or previously treated of Multiple Myeloma (supporting evidence may include MRI, CT, tumor markers, and pathology report);
  • Patients who had scheduled both standard-of-care imaging (FDG PET/CT) and cd38 PET/CT scans;
  • Patients who were able to provide (signed by participant, parent or legal representative) and assent according to the guidelines of the Clinical Research Ethics Committee.

Exclusion criteria

Exclusion Criteria:

  • The inability or unwillingness of the research participant or legal representative to provide written .
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Diagnostic
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
100 participants (estimated)

Study arms

  • Experimental
    CD38 PET/CT

    Each subject receives a single intravenous injection of radiolabeld CD38 and undergoes PET/CT imaging within the specified time.

    Diagnostic Test: standard-of-care imaging (FDG PET/CT), CD38 PET/CT

Interventions

  • Diagnostic teststandard-of-care imaging (FDG PET/CT), CD38 PET/CT

    Each subject receives a single intravenous injection of standard-of-care imaging radiopharmaceutical (FDG) and CD38, and undergoes PET/CT imaging within the specified time.

06

What researchers measure

Primary outcomes

  1. Diagnostic efficacy

    The sensitivity, specificity, and accuracy of standard-of-care imaging (FDG PET/CT) and CD38 PET/CT were calculated and compared to evaluate the diagnostic accuracy.

    Time frame: 3 year

Secondary outcomes

  1. Number of lesions

    The numbers of positive primary and metastatic lesions of standard-of-care imaging (FDG PET/CT) and CD38 PET/CT were recorded by visual interpretation.

    Time frame: 3 year

  2. SUV

    Standardized uptake value (SUV) of standard-of-care imaging (FDG PET/CT) and CD38 PET/CT for each target lesion of subject or suspected primary tumor or/and metastasis.

    Time frame: 3 year

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jul 2026 (actual). Primary completion is estimated for Dec 2030, 53 months after the start.

Of 172 non-industry interventional studies with no phase under Multiple Myeloma, half reached primary completion within 37 months of starting (the median), counting those still running; a quarter within 21 and three quarters within 81. This study's planned 53 months is above that.

Counting every sponsor, half of 186 studies reached it within 38 months; a quarter within 20 and three quarters within 79.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 20, 2026
First posted
Aug 24, 2026
StartActual
Jul 7, 2026
Primary completionEst.
Dec 31, 2030
CompletionEst.
Dec 31, 2030
Last update
Aug 24, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 24, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07782944
Lead sponsor
Guilin Medical University, China
Responsible party
Wei Fu (Department of Nuclear Medicine, Guilin Medical University, China) — Principal investigator
First posted
Aug 24, 2026
Start date
Jul 7, 2026
Primary completion
Dec 31, 2030 (estimated)
Completion
Dec 31, 2030 (estimated)
Last update
Aug 24, 2026

Study contacts

Xingyu Mu, M.D.
Contact
muxingyu1992@hotmail.com
86 13347631119

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion